Physician profile
Barry Keith Abramson
NPI 1922025980
$7,484.87
in general payments reported to CMS, 2019-2025
30 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $286 · 2021: $428 · 2022: $1,717 · 2023: $1,774 · 2024: $1,543 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878 · Education: $14.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.29 |
| Education | $14.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,201.68 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $745.24 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $708.03 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $582.90 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $471.39 | 2019-2025 | |
| Genzyme Corporation | $395.06 | 2022-2024 | |
| Celgene Corporation | $353.00 | 2019-2024 | Zeposia |
| Gilead Sciences, INC. | $276.09 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $230.56 | 2019 | |
| Ardelyx, INC. | $223.73 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $219.35 | 2019-2025 | Sucraid, Sucraid |
| Dova Pharmaceuticals | $149.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $121.76 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $105.08 | 2021 | |
| Amgen INC. | $84.55 | 2022-2023 | Avsola, Amjevita |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $84.46 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $80.66 | 2022-2023 | Linzess |
| Braintree Laboratories, INC. | $80.57 | 2021-2025 | Suflave |
| Lilly USA, LLC | $54.39 | 2024 | Omvoh |
| Ucb, INC. | $53.50 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $48.93 | 2023 | |
| Intercept Pharmaceuticals, INC. | $34.18 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $33.95 | 2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.21 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $25.81 | 2022 | |
| Shire North American Group INC | $23.77 | 2019 | |
| Allergan, INC. | $19.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.97 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $15.50 | 2024 | Resmetirom |
| Celltrion USA INC. | $14.15 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Abramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.